By a News Reporter-Staff News Editor at Women’s Health Weekly -- Investigators publish new report on Pregnancy Complications - Postpartum Hemorrhage. According to news reporting originating in Paris, France, by NewsRx journalists, research stated, “To compare the rates of invasive procedures (surgical or vascular) for hemorrhage control between a perinatal network that routinely used intrauterine balloon tamponade and another perinatal network that did not in postpartum hemorrhage management. This population-based retrospective cohort study included all women (72,529) delivering between 2011 and 2012 in the 19 maternity units in two French perinatal networks: a pilot (in which balloon tamponade was used) and a control network.”
The news reporters obtained a quote from the research from Pasteur Institute, “Outcomes were assessed based on discharge abstract data from the national French medical information system. General and obstetric characteristics were included in two separate multivariate logistic models according to the mode of delivery (vaginal and cesarean) to estimate the independent association of the network with invasive procedures. Invasive procedures (pelvic vessel ligation, arterial embolization, hysterectomy) were used in 298 women and in 4.1 per 1,000 deliveries (95% CI 3.7-4.6). The proportion of women with at least one invasive procedure was significantly lower in the pilot network (3.0/1,000 vs 5.1/1,000, P<.01). Among women who delivered vaginally, the use of arterial embolization was also significantly lower in the pilot than the control network (0.2/1,000 vs 3.7/1,000, P<.01) as it was for those who delivered by cesarean (1.3/1,000 vs 5.7/1,000, P<.01). After controlling for potential confounding factors, the risk of an invasive procedure among women who delivered vaginally remained significantly lower in the pilot network (adjusted odds ratio [OR] 0.14, 95% CI 0.08-0.27), but not for women who delivered by cesarean (adjusted OR 1.19, 95% CI 0.87-1.61).”
According to the news reporters, the research concluded: “The use of intrauterine balloon tamponade in routine clinical practice was associated with a significantly lower use of invasive procedures for hemorrhage control among women undergoing vaginal delivery.”
For more information on this research see: Intrauterine Balloon Tamponade for Severe Postpartum Hemorrhage. Obstetrics and Gynecology , 2018;131(1):143-149. Obstetrics and Gynecology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; Obstetrics and Gynecology - http://journals.lww.com/greenjournal/pages/default.aspx)
Our news correspondents report that additional information may be obtained by contacting M. Revert, Univ Paris Saclay, Inst Pasteur, INSERMUVSQ, Biostat Biomath Pharmacoepidemiol & Infect Dis B2, Paris, France. Additional authors for this research include P. Rozenberg, J. Cottenet and C. Quantin.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
CITATION: (2018-05-03), Findings in Postpartum Hemorrhage Reported from Pasteur Institute (Intrauterine Balloon Tamponade for Severe Postpartum Hemorrhage), Women’s Health Weekly, 166, ISSN: 1532-4729, BUTTER® ID: 015569045
From the newsletter Women’s Health Weekly.
https://www.newsrx.com/Butter/#!Search:a=15569045
This is a NewsRx® article created by NewsRx® and posted by NewsRx®. As proof that we are NewsRx® posting NewsRx® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.
We have been in business for more than 20 years and our full contact information is available on our main corporate website.
We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.
NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.